SEC Form 4 · accession 0001209191-17-065094
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Dec 11, 2017
Accepted (ET)
Dec 11, 2017 · 6:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Dec 11, 2017 | S | 20,090 | $140.31 | D | 237,407 | D | |
| Common StockF3,F4 | Dec 11, 2017 | S | 87,578 | $141.35 | D | 149,829 | D | |
| Common StockF3,F5 | Dec 11, 2017 | S | 12,134 | $142.21 | D | 137,695 | D | |
| Common StockF3,F6 | Dec 11, 2017 | S | 5,198 | $143.39 | D | 132,497 | D | |
| Common Stock | holding | — | — | — | 440 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $140.31 (range $139.85 to 140.84).
- F3Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $141.35 (range $140.86 to $141.85).
- F5Open market sales reported on this line occurred at a weighted average price of $142.21 (range $141.86 to $142.79).
- F6Open market sales reported on this line occurred at a weighted average price of $143.39 (range $142.90 to $143.85).